atrasentan has been researched along with Diabetic Retinopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batlle, D; Chou, JC; Fawzi, AA; Rollins, SD; Ye, M | 1 |
| Harris, NR; Leskova, W; Wang, Z; Yadav, AS | 1 |
2 other study(ies) available for atrasentan and Diabetic Retinopathy
| Article | Year |
|---|---|
Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice.
Topics: Animals; Apoptosis; Atrasentan; Cell Count; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin Receptor Antagonists; Endothelin-1; Female; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Inbred C57BL; Pyrrolidines; Retinal Ganglion Cells; Retinal Vessels | 2014 |
Attenuation of streptozotocin-induced microvascular changes in the mouse retina with the endothelin receptor A antagonist atrasentan.
Topics: Administration, Oral; Animals; Atrasentan; Blood Flow Velocity; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin A Receptor Antagonists; Endothelin-1; Fluorescent Antibody Technique, Indirect; Male; Mice; Mice, Inbred C57BL; Platelet Endothelial Cell Adhesion Molecule-1; Pyrrolidines; Regional Blood Flow; Retinal Vessels | 2010 |